AZNAcerta Pharma BVRunning, no new patients
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
Chronic Lymphocytic Leukemia
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 535 (final count)
- Started
- Jun 26, 2015
- Main results expected
- Feb 8, 2019
- Fully finished
- Sep 15, 2026
- Results posted
- Jan 10, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B
Measured over: IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02475681 · record last updated 2026-08-25 · checked 2026-11-09 15:47 UTC